ZNF671 restrains endometrial cancer cell growth and stemness through the Wnt/β-catenin pathway

Endometrial cancer is a common malignant cancer in women, which poses serious health risks. Multifarious cancers have been shown to be suppressed by Zinc finger protein 671 (ZNF671). However, the precise regulatory impact of ZNF671 on endometrial cancer progression remains unclear. This study investigated ZNF671’s role in endometrial cancer. The Ualcan online database revealed that ZNF671 exhibited low expression in uterine corpus endometrial carcinoma (UCEC) tissues. Endometrial cancer patients who exhibited low ZNF671 expression suffered poor prognosis. ZNF671 also retarded tumor growth in endometrial cancer. Cell invasion and migration were restrained by ZNF671. In addition, ZNF671 inhibited endometrial cancer stemness. Eventually, ZNF671 suppressed the Wnt/β-catenin pathway. In conclusion, ZNF671 restrained both cell growth and stemness in endometrial cancer through the Wnt/β-catenin pathway. ZNF671 may serve as a bio-target for endometrial cancer treatment.

ZNF671; Endometrial cancer; Stemness; The Wnt/β-catenin pathway

[1] Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nature Reviews Disease Primers. 2021; 7: 88.

[2] Åkesson Å, Adok C, Dahm-Kähler P. Recurrence and survival in endometrioid endometrial cancer—a population-based cohort study. Gynecologic Oncology. 2023; 168: 127–134.

[3] Sheikh MA, Althouse AD, Freese KE, Soisson S, Edwards RP, Welburn S, et al. USA endometrial cancer projections to 2030: should we be concerned? Future Oncology. 2014; 10: 2561–2568.

[4] Arend RC, Jones BA, Martinez A, Goodfellow P. Endometrial cancer: molecular markers and management of advanced stage disease. Gynecologic Oncology. 2018; 150: 569–580.

[5] Cassier PA, Navaridas R, Bellina M, Rama N, Ducarouge B, Hernandez-Vargas H, et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature. 2023; 620: 409–416.

[6] Gao K, Shi Q, Gu Y, Yang W, He Y, Lv Z, et al. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1–PD-L1 axis. Cell Death & Differentiation. 2023; 30: 475–487.

[7] Wu W, Chen X, Liu X, Bao HJ, Li QH, Xian JY, et al. SNORD60 promotes the tumorigenesis and progression of endometrial cancer through binding PIK3CA and regulating PI3K/AKT/mTOR signaling pathway. Molecular Carcinogenesis. 2023; 62: 413–426.

[8] Sun M, Ju J, Ding Y, Zhao C, Tian C. The signaling pathways regulated by KRAB zinc-finger proteins in cancer. Biochimica Et Biophysica Acta (BBA)—Reviews on Cancer. 2022; 1877: 188731.

[9] Wang Y, Chen F, Wei C, Sun L, Liu C, Yang L, et al. Zinc finger protein 671 has a cancer-inhibiting function in colorectal carcinoma via the deactivation of Notch signaling. Toxicology and Applied Pharmacology. 2023; 458: 116326.

[10] Zhang W, Liu T, Li X, Li T, Ma X, Zhao D, et al. Increased methylation of ZNF671 suppresses tumor progression by promoting MAPK6 transcription in laryngeal carcinoma. International Journal of Biological Sciences. 2023; 19: 2443–2457.

[11] Zhan W, Li Y, Liu X, Zheng C, Fu Y. ZNF671 Inhibits the Proliferation and Metastasis of NSCLC via the Wnt/β-catenin pathway. Cancer Management and Research. 2020; 12: 599–610.

[12] Zhang J, Wen X, Liu N, Li Y, Tang X, Wang Y, et al. Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. Journal of Experimental & Clinical Cancer Research. 2017; 36: 147.

[13] Prasad S, Ramachandran S, Gupta N, Kaushik I, Srivastava SK. Cancer cells stemness: a doorstep to targeted therapy. Biochimica Et Biophysica Acta (BBA)—Molecular Basis of Disease. 2020; 1866: 165424.

[14] Aponte PM, Caicedo A. Stemness in cancer: stem cells, cancer stem cells, and their microenvironment. Stem Cells International. 2017; 2017: 5619472.

[15] Liang C, Jiang Y, Sun L. Vitexin suppresses the proliferation, angiogenesis and stemness of endometrial cancer through the PI3K/AKT pathway. Pharmaceutical Biology. 2023; 61: 581–589.

[16] Wu X, Wang Y, Zhong W, Cheng H, Tian Z. RNA binding protein RNPC1 suppresses the stemness of human endometrial cancer cells via stabilizing MST1/2 mRNA. Medical Science Monitor. 2020; 26: e921389.

[17] Chu Y, Jin X, Guo X. MCM2 promotes the stemness of endometrial cancer cells via the Akt/β-catenin pathway. Neoplasma. 2023; 70: 610–620.

[18] Zhao T, Sun R, Ma X, Wei L, Hou Y, Song K, et al. Overexpression of LPCAT1 enhances endometrial cancer stemness and metastasis by changing lipid components and activating the TGF/β-Smad2/3 signaling pathway. Acta Biochimica et Biophysica Sinica. 2022; 54: 904–916.

[19] Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology & Oncology. 2020; 13: 165.

[20] Krishnamurthy N, Kurzrock R. Targeting the Wnt/β-catenin pathway in cancer: update on effectors and inhibitors. Cancer Treatment Reviews. 2018; 62: 50–60.

[21] Wang ZM, Wan XH, Sang GY, Zhao JD, Zhu QY, Wang DM. miR-15a-5p suppresses endometrial cancer cell growth via Wnt/β-catenin signaling pathway by inhibiting WNT3A. European Review for Medical and Pharmacological Sciences. 2017; 21: 4810–4818.

[22] Zheng ZM, Wang YY, Chen M, Yang HL, Lai ZZ, Li MQ, et al. FBXO17 inhibits the Wnt/β-catenin pathway and proliferation of ishikawa cells. International Journal of Medical Sciences. 2022; 19: 1430–1441.

[23] Zhang B, Ji J, Hu M, Zhou X, Nie Q, Xu H, et al. WIF1 promoter hypermethylation induce endometrial carcinogenesis through the Wnt/β-catenin signaling pathway. American Journal of Reproductive Immunology. 2023; 90: e13743.

[24] Han X, Cao Y, Wang K, Zhu G. HMGA1 facilitates tumor progression through regulating Wnt/β-catenin pathway in endometrial cancer. Biomedicine & Pharmacotherapy. 2016; 82: 312–318.